Kojima M, Ohe H, Watanabe H
Department of Urology, Kyoto Prefectural University of Medicine, Japan.
Br J Urol. 1995 Apr;75(4):492-7. doi: 10.1111/j.1464-410x.1995.tb07271.x.
To evaluate the clinical usefulness of the kinetic analysis of prostatic volume in the prognosis of patients with Stage D prostatic cancer treated using luteinizing hormone-releasing hormone (LHRH) analogues.
The reduction of prostatic volume was monitored in 12 patients with Stage D prostatic cancer using transrectal ultrasonography (TRUS) after treatment with LHRH analogues. Data obtained from the kinetic analysis of prostatic volume were compared with the prognosis.
All the patients having a reduction time, tau (derived from the kinetic analysis of prostatic volume change with time), of less than 41 days had neither clinical progression within 15 months nor death caused by prostatic cancer during the 5-year follow-up, while the disease-specific 5-year survival rate in patients having a tau of greater than 42 days was as low as 17%. The difference in both the progression and disease-specific survival between these groups was statistically significant (P < 0.05) despite the limited number of patients. In contrast, conventional prognostic parameters showed no significant predictability for prognosis with the exception of prostatic acid phosphatase, which correlated strongly with the occurrence of progression within 15 months.
The kinetic analysis of the change of prostatic volume using TRUS shows promise in the prognosis of the patients with Stage D prostatic cancer.
评估前列腺体积动力学分析在使用促黄体生成素释放激素（LHRH）类似物治疗的D期前列腺癌患者预后中的临床应用价值。
对12例D期前列腺癌患者在使用LHRH类似物治疗后，采用经直肠超声检查（TRUS）监测前列腺体积的缩小情况。将从前列腺体积动力学分析获得的数据与预后情况进行比较。
所有前列腺体积缩小时间（τ，通过前列腺体积随时间变化的动力学分析得出）少于41天的患者，在15个月内均无临床进展，且在5年随访期间无前列腺癌导致的死亡，而τ大于42天的患者5年疾病特异性生存率低至17%。尽管患者数量有限，但这些组之间在进展和疾病特异性生存方面的差异具有统计学意义（P < 0.05）。相比之下，除了与15个月内进展的发生密切相关的前列腺酸性磷酸酶外，传统的预后参数对预后没有显著的预测能力。
使用TRUS对前列腺体积变化进行动力学分析在D期前列腺癌患者的预后评估中显示出前景。
